JI
Insider
Jula Inrig
EVP, Head of R&D & CMOJula Inrig (EVP, Head of R&D & CMO) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Travere Therapeutics, Inc. (TVTX). The largest single filing was $2.8M of TVTX (44,274 sh across 3 lots, as filed), executed Sep 15.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
5
0 buys · 5 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$4.9M
shares × price, as filed
Last traded
Sep 15
Filed Sep 17
Median ADV $123.0M across their filed names
Open performance→Volume by month
Buys $0
Sells $4.9M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
5 filings
Sector per market data · by filing · past 12 months
Most traded names
TVTXRecent filings
TVTXSALE
Travere Therapeutics, Inc.
View filing →
$2.8M44,274 sh across 3 lots
Exec Sep 15
Filed Sep 17 · 9:33 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $1.0M
22,174 sh across 2 lots
Exec May 4
Filed May 6 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $303K
7,215 sh × $41.93
Exec Apr 14
Filed Apr 15 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $223K
6,956 sh × $32.12
Exec Feb 3
Filed Feb 3 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $630K
15,000 sh × $42.00
Exec Dec 24 2025
Filed Dec 29 2025 · 5:30 PM ET